Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CNN-PepPred, an open-source tool to create convolutional NN models for the discovery of patterns in peptide sets-application to peptide-MHC class II binding prediction

  • Junet, Valentin|||0000-0002-6138-0612
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
Summary: The ability to unveil binding patterns in peptide sets has important applications in several biomedical areas, including the development of vaccines. We present an open-source tool, CNN-PepPred, that uses convolutional neural networks to discover such patterns, along with its application to peptide-HLA class II binding prediction. The tool can be used locally on different operating systems, with CPUs or GPUs, to train, evaluate, apply and visualize models. Availability and implementation: CNN-PepPred is freely available as a Python tool with a detailed User's Guide at https://github.com/ComputBiol-IBB/CNN-PepPred. The site includes the peptide sets used in this study, extracted from IEDB (www.iedb.org). Supplementary information: Supplementary data are available at Bioinformatics online.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Methods to Develop an in silico Clinical Trial, Computational Head-to-Head Comparison of Lisdexamfetamine and Methylphenidate

  • Gutiérrez-Casares, José Ramón
  • Quintero, Javier
  • Jorba, Guillem|||0000-0001-5209-5353
  • Junet, Valentin|||0000-0002-6138-0612
  • Martínez Perea, Vicente|||0000-0001-5193-715X
  • Pozo-Rubio, Tamara
  • Oliva Miguel, Baldomero|||0000-0003-0702-0250
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Mas, José Manuel
  • Montoto, Carmen
Regulatory agencies encourage computer modeling and simulation to reduce the time and cost of clinical trials. Although still not classified in formal guidelines, system biology-based models represent a powerful tool for generating hypotheses with great molecular detail. Herein, we have applied a mechanistic head-to-head in silico clinical trial (ISCT) between two treatments for attention-deficit/hyperactivity disorder, to wit lisdexamfetamine (LDX) and methylphenidate (MPH). The ISCT was generated through three phases comprising (i) the molecular characterization of drugs and pathologies, (ii) the generation of adult and children virtual populations (vPOPs) totaling 2,600 individuals and the creation of physiologically based pharmacokinetic (PBPK) and quantitative systems pharmacology (QSP) models, and (iii) data analysis with artificial intelligence methods. The characteristics of our vPOPs were in close agreement with real reference populations extracted from clinical trials, as did our PBPK models with in vivo parameters. The mechanisms of action of LDX and MPH were obtained from QSP models combining PBPK modeling of dosing schemes and systems biology-based modeling technology, i.e., therapeutic performance mapping system. The step-by-step process described here to undertake a head-to-head ISCT would allow obtaining mechanistic conclusions that could be extrapolated or used for predictions to a certain extent at the clinical level. Altogether, these computational techniques are proven an excellent tool for hypothesis-generation and would help reach a personalized medicine.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MMPred, a tool to predict peptide mimicry events in MHC class II recognition

  • Guerri, Filippo
  • Junet, Valentin|||0000-0002-6138-0612
  • Farrés, Judith|||0000-0002-0958-0510
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
We present MMPred, a software tool that integrates epitope prediction and sequence alignment algorithms to streamline the computational analysis of molecular mimicry events in autoimmune diseases. Starting with two protein or peptide sets (e.g., from human and SARS-CoV-2), MMPred facilitates the generation, investigation, and testing of mimicry hypotheses by providing epitope predictions specifically for MHC class II alleles, which are frequently implicated in autoimmunity. However, the tool is easily extendable to MHC class I predictions by incorporating pre-trained models from CNN-PepPred and NetMHCpan. To evaluate MMPred's ability to produce biologically meaningful insights, we conducted a comprehensive assessment involving i) predicting associations between known HLA class II human autoepitopes and microbial-peptide mimicry, ii) interpreting these predictions within a systems biology framework to identify potential functional links between the predicted autoantigens and pathophysiological pathways related to autoimmune diseases, and iii) analyzing illustrative cases in the context of SARS-CoV-2 infection and autoimmunity. MMPred code and user guide are made freely available at https://github.com/ComputBiol-IBB/MMPRED.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis

  • Coto-Segura, P|||0000-0002-6455-4825
  • Segú-Vergés, Cristina|||0000-0002-8215-872X
  • Martorell, Antonio|||0000-0003-1378-1590
  • Moreno-Ramírez, David|||0000-0002-1301-7974
  • Jorba, Guillem|||0000-0001-5209-5353
  • Junet, Valentin|||0000-0002-6138-0612
  • Guerri, Filippo
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Oliva Miguel, Baldomero|||0000-0003-0702-0250
  • Cara, Carlos
  • Suárez-Magdalena, Olaya
  • Abraham, Sonya
  • Mas, José Manuel
Psoriasis is a chronic immune-mediated inflammatory systemic disease with skin manifestations characterized by erythematous, scaly, itchy and/or painful plaques resulting from hyperproliferation of keratinocytes. Certolizumab pegol [CZP], a PEGylated antigen binding fragment of a humanized monoclonal antibody against TNF-alpha, is approved for the treatment of moderate-to-severe plaque psoriasis. Patients with psoriasis present clinical and molecular variability, affecting response to treatment. Herein, we utilized an in silico approach to model the effects of CZP in a virtual population (vPop) with moderate-to-severe psoriasis. Our proof-of-concept study aims to assess the performance of our model in generating a vPop and defining CZP response variability based on patient profiles. We built a quantitative systems pharmacology (QSP) model of a clinical trial-like vPop with moderate-to-severe psoriasis treated with two dosing schemes of CZP (200 mg and 400 mg, both every two weeks for 16 weeks, starting with a loading dose of CZP 400 mg at weeks 0, 2, and 4). We applied different modelling approaches: (i) an algorithm to generate vPop according to reference population values and comorbidity frequencies in real-world populations; (ii) physiologically based pharmacokinetic (PBPK) models of CZP dosing schemes in each virtual patient; and (iii) systems biology-based models of the mechanism of action (MoA) of the drug. The combination of our different modelling approaches yielded a vPop distribution and a PBPK model that aligned with existing literature. Our systems biology and QSP models reproduced known biological and clinical activity, presenting outcomes correlating with clinical efficacy measures. We identified distinct clusters of virtual patients based on their psoriasis-related protein predicted activity when treated with CZP, which could help unravel differences in drug efficacy in diverse subpopulations. Moreover, our models revealed clusters of MoA solutions irrespective of the dosing regimen employed. Our study provided patient specific QSP models that reproduced clinical and molecular efficacy features, supporting the use of computational methods as modelling strategy to explore drug response variability. This might shed light on the differences in drug efficacy in diverse subpopulations, especially useful in complex diseases such as psoriasis, through the generation of mechanistically based hypotheses.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan

  • Jorba Argemí, Guillem
  • Aguirre Plans, Joaquim, 1993-
  • Junet, Valentin
  • Segú-Vergés, Cristina
  • Ruiz, José Luis
  • Pujol, Albert
  • Fernández Fuentes, Narcís
  • Mas, José Manuel
  • Oliva Miguel, Baldomero
Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of different responses depending on the patient. Exploring this collection of mechanisms is one of the clues for a future personalized medicine. The Therapeutic Performance Mapping System (TPMS) is a Systems Biology approach that generates multiple models of the mechanism of action of a drug. Each molecular mechanism generated could be associated to particular individuals, here defined as prototype-patients, hence the generation of models using TPMS technology may be used for detecting adverse effects to specific patients. TPMS operates by (1) modelling the responses in humans with an accurate description of a protein network and (2) applying a Multilayer Perceptron-like and sampling strategy to find all plausible solutions. In the present study, TPMS is applied to explore the diversity of mechanisms of action of the drug combination sacubitril/valsartan. We use TPMS to generate a wide range of models explaining the relationship between sacubitril/valsartan and heart failure (the indication), as well as evaluating their association with macular degeneration (a potential adverse effect). Among the models generated, we identify a set of mechanisms of action associated to a better response in terms of heart failure treatment, which could also be associated to macular degeneration development. Finally, a set of 30 potential biomarkers are proposed to identify mechanisms (or prototype-patients) more prone of suffering macular degeneration when presenting good heart failure response. All prototype-patients models generated are completely theoretical and therefore they do not necessarily involve clinical effects in real patients. Data and accession to software are available at http://sbi.upf.edu/data/tpms/., Public funders provided support for authors salaries: JAP, NFF and BO received support from the Spanish Ministry of Economy (MINECO) [BIO2017-85329-R] [RYC-2015-17519]; “Unidad de Excelencia María de Maeztu”, funded by the Spanish Ministry of Economy [ref: MDM-2014-0370]. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I+D+i 2013-2016, funded by ISCIII and FEDER. GJ has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765912. VJ is part of a project (COSMIC; www.cosmic-h2020.eu) that has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765158. Funding for publication is from Agència de Gestió D'ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Methods to develop an in silico clinical trial: computational head-to-head comparison of lisdexamfetamine and methylphenidate

  • Gutiérrez-Casares, José Ramón
  • Quintero, Javier
  • Jorba Argemí, Guillem
  • Junet, Valentin
  • Martínez, Vicente
  • Pozo-Rubio, Tamara
  • Oliva Miguel, Baldomero
  • Daura, Xavier
  • Mas, José Manuel
  • Montoto, Carmen
Regulatory agencies encourage computer modeling and simulation to reduce the time and cost of clinical trials. Although still not classified in formal guidelines, system biology-based models represent a powerful tool for generating hypotheses with great molecular detail. Herein, we have applied a mechanistic head-to-head in silico clinical trial (ISCT) between two treatments for attention-deficit/hyperactivity disorder, to wit lisdexamfetamine (LDX) and methylphenidate (MPH). The ISCT was generated through three phases comprising (i) the molecular characterization of drugs and pathologies, (ii) the generation of adult and children virtual populations (vPOPs) totaling 2,600 individuals and the creation of physiologically based pharmacokinetic (PBPK) and quantitative systems pharmacology (QSP) models, and (iii) data analysis with artificial intelligence methods. The characteristics of our vPOPs were in close agreement with real reference populations extracted from clinical trials, as did our PBPK models with in vivo parameters. The mechanisms of action of LDX and MPH were obtained from QSP models combining PBPK modeling of dosing schemes and systems biology-based modeling technology, i.e., therapeutic performance mapping system. The step-by-step process described here to undertake a head-to-head ISCT would allow obtaining mechanistic conclusions that could be extrapolated or used for predictions to a certain extent at the clinical level. Altogether, these computational techniques are proven an excellent tool for hypothesis-generation and would help reach a personalized medicine., This study was funded by Takeda. Public funders provided support for some of the authors' salaries: GJ has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 765912. VJ is part of a project (COSMIC; www.cosmic-h2020.eu) that has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 765158.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A decision support system based on artificial intelligence and systems biology for the simulation of pancreatic cancer patient status

  • Junet, Valentin
  • Matos Filipe, Pedro
  • García-Illarramendi, Juan Manuel
  • Ramírez, Esther
  • Oliva Miguel, Baldomero
  • Farrés, Judith
  • Daura, Xavier
  • Mas, José Manuel
  • Morales-Barrera, Rafael
Oncology treatments require continuous individual adjustment based on the measurement of multiple clinical parameters. Prediction tools exploiting the patterns present in the clinical data could be used to assist decision making and ease the burden associated to the interpretation of all these parameters. The goal of this study was to predict the evolution of patients with pancreatic cancer at their next visit using information routinely recorded in health records, providing a decision-support system for clinicians. We selected hematological variables as the visit's clinical outcomes, under the assumption that they can be predictive of the evolution of the patient. Multivariate models based on regression trees were generated to predict next-visit values for each of the clinical outcomes selected, based on the longitudinal clinical data as well as on molecular data sets streaming from in silico simulations of individual patient status at each visit. The models predict, with a mean prediction score (balanced accuracy) of 0.79, the evolution trends of eosinophils, leukocytes, monocytes, and platelets. Time span between visits and neutropenia were among the most common factors contributing to the predicted evolution. The inclusion of molecular variables from the systems-biology in silico simulations provided a molecular background for the observed variations in the selected outcome variables, mostly in relation to the regulation of hematopoiesis. In spite of its limitations, this study serves as a proof of concept for the application of next-visit prediction tools in real-world settings, even when available data sets are small., V.J. is part of a project (COSMIC) that has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 765158. P.M.F. receives funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 860303. J.M.G.I. receives funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 859962.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis

  • Coto-Segura, Pablo
  • Segú-Vergés, Cristina
  • Martorell, Antonio
  • Moreno-Ramírez, David
  • Jorba Argemí, Guillem
  • Junet, Valentin
  • Guerri, Filippo
  • Daura, Xavier
  • Oliva Miguel, Baldomero
  • Cara, Carlos
  • Suárez-Magdalena, Olaya
  • Abraham, Sonya
  • Mas, José Manuel
Background: Psoriasis is a chronic immune-mediated inflammatory systemic disease with skin manifestations characterized by erythematous, scaly, itchy and/or painful plaques resulting from hyperproliferation of keratinocytes. Certolizumab pegol [CZP], a PEGylated antigen binding fragment of a humanized monoclonal antibody against TNF-alpha, is approved for the treatment of moderate-to-severe plaque psoriasis. Patients with psoriasis present clinical and molecular variability, affecting response to treatment. Herein, we utilized an in silico approach to model the effects of CZP in a virtual population (vPop) with moderate-to-severe psoriasis. Our proof-of-concept study aims to assess the performance of our model in generating a vPop and defining CZP response variability based on patient profiles. Methods: We built a quantitative systems pharmacology (QSP) model of a clinical trial-like vPop with moderate-to-severe psoriasis treated with two dosing schemes of CZP (200 mg and 400 mg, both every two weeks for 16 weeks, starting with a loading dose of CZP 400 mg at weeks 0, 2, and 4). We applied different modelling approaches: (i) an algorithm to generate vPop according to reference population values and comorbidity frequencies in real-world populations; (ii) physiologically based pharmacokinetic (PBPK) models of CZP dosing schemes in each virtual patient; and (iii) systems biology-based models of the mechanism of action (MoA) of the drug. Results: The combination of our different modelling approaches yielded a vPop distribution and a PBPK model that aligned with existing literature. Our systems biology and QSP models reproduced known biological and clinical activity, presenting outcomes correlating with clinical efficacy measures. We identified distinct clusters of virtual patients based on their psoriasis-related protein predicted activity when treated with CZP, which could help unravel differences in drug efficacy in diverse subpopulations. Moreover, our models revealed clusters of MoA solutions irrespective of the dosing regimen employed. Conclusion: Our study provided patient specific QSP models that reproduced clinical and molecular efficacy features, supporting the use of computational methods as modelling strategy to explore drug response variability. This might shed light on the differences in drug efficacy in diverse subpopulations, especially useful in complex diseases such as psoriasis, through the generation of mechanistically based hypotheses., The study was funded by UCB Pharma and Anaxomics Biotech. Copy-editing was funded by UCB Pharma. Article processing fees were provided by UCB Pharma. Public funders provided support for some of the authors’ salaries: VJ has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765158 (COSMIC; www.cosmic-h2020.eu); GJ has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 765912; FG has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 813545. The funder UCB Biopharma was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan

  • Jorba Argemí, Guillem
  • Aguirre Plans, Joaquim, 1993-
  • Junet, Valentin
  • Segú-Vergés, Cristina
  • Ruiz, José Luis
  • Pujol, Albert
  • Fernández Fuentes, Narcís
  • Mas, José Manuel
  • Oliva Miguel, Baldomero
Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of different responses depending on the patient. Exploring this collection of mechanisms is one of the clues for a future personalized medicine. The Therapeutic Performance Mapping System (TPMS) is a Systems Biology approach that generates multiple models of the mechanism of action of a drug. Each molecular mechanism generated could be associated to particular individuals, here defined as prototype-patients, hence the generation of models using TPMS technology may be used for detecting adverse effects to specific patients. TPMS operates by (1) modelling the responses in humans with an accurate description of a protein network and (2) applying a Multilayer Perceptron-like and sampling strategy to find all plausible solutions. In the present study, TPMS is applied to explore the diversity of mechanisms of action of the drug combination sacubitril/valsartan. We use TPMS to generate a wide range of models explaining the relationship between sacubitril/valsartan and heart failure (the indication), as well as evaluating their association with macular degeneration (a potential adverse effect). Among the models generated, we identify a set of mechanisms of action associated to a better response in terms of heart failure treatment, which could also be associated to macular degeneration development. Finally, a set of 30 potential biomarkers are proposed to identify mechanisms (or prototype-patients) more prone of suffering macular degeneration when presenting good heart failure response. All prototype-patients models generated are completely theoretical and therefore they do not necessarily involve clinical effects in real patients. Data and accession to software are available at http://sbi.upf.edu/data/tpms/., Public funders provided support for authors salaries: JAP, NFF and BO received support from the Spanish Ministry of Economy (MINECO) [BIO2017-85329-R] [RYC-2015-17519]; “Unidad de Excelencia María de Maeztu”, funded by the Spanish Ministry of Economy [ref: MDM-2014-0370]. The Research Programme on Biomedical Informatics (GRIB) is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I+D+i 2013-2016, funded by ISCIII and FEDER. GJ has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765912. VJ is part of a project (COSMIC; www.cosmic-h2020.eu) that has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765158. Funding for publication is from Agència de Gestió D'ajuts Universitaris i de Recerca Generalitat de Catalunya [2017SGR00519]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis

  • Coto-Segura, Pablo
  • Segú-Vergés, Cristina
  • Martorell, Antonio
  • Moreno-Ramírez, David
  • Jorba Argemí, Guillem
  • Junet, Valentin
  • Guerri, Filippo
  • Daura, Xavier
  • Oliva Miguel, Baldomero
  • Cara, Carlos
  • Suárez-Magdalena, Olaya
  • Abraham, Sonya
  • Mas, José Manuel
Background: Psoriasis is a chronic immune-mediated inflammatory systemic disease with skin manifestations characterized by erythematous, scaly, itchy and/or painful plaques resulting from hyperproliferation of keratinocytes. Certolizumab pegol [CZP], a PEGylated antigen binding fragment of a humanized monoclonal antibody against TNF-alpha, is approved for the treatment of moderate-to-severe plaque psoriasis. Patients with psoriasis present clinical and molecular variability, affecting response to treatment. Herein, we utilized an in silico approach to model the effects of CZP in a virtual population (vPop) with moderate-to-severe psoriasis. Our proof-of-concept study aims to assess the performance of our model in generating a vPop and defining CZP response variability based on patient profiles. Methods: We built a quantitative systems pharmacology (QSP) model of a clinical trial-like vPop with moderate-to-severe psoriasis treated with two dosing schemes of CZP (200 mg and 400 mg, both every two weeks for 16 weeks, starting with a loading dose of CZP 400 mg at weeks 0, 2, and 4). We applied different modelling approaches: (i) an algorithm to generate vPop according to reference population values and comorbidity frequencies in real-world populations; (ii) physiologically based pharmacokinetic (PBPK) models of CZP dosing schemes in each virtual patient; and (iii) systems biology-based models of the mechanism of action (MoA) of the drug. Results: The combination of our different modelling approaches yielded a vPop distribution and a PBPK model that aligned with existing literature. Our systems biology and QSP models reproduced known biological and clinical activity, presenting outcomes correlating with clinical efficacy measures. We identified distinct clusters of virtual patients based on their psoriasis-related protein predicted activity when treated with CZP, which could help unravel differences in drug efficacy in diverse subpopulations. Moreover, our models revealed clusters of MoA solutions irrespective of the dosing regimen employed. Conclusion: Our study provided patient specific QSP models that reproduced clinical and molecular efficacy features, supporting the use of computational methods as modelling strategy to explore drug response variability. This might shed light on the differences in drug efficacy in diverse subpopulations, especially useful in complex diseases such as psoriasis, through the generation of mechanistically based hypotheses., The study was funded by UCB Pharma and Anaxomics Biotech. Copy-editing was funded by UCB Pharma. Article processing fees were provided by UCB Pharma. Public funders provided support for some of the authors’ salaries: VJ has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765158 (COSMIC; www.cosmic-h2020.eu); GJ has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 765912; FG has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 813545. The funder UCB Biopharma was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A decision support system based on artificial intelligence and systems biology for the simulation of pancreatic cancer patient status

  • Junet, Valentin
  • Matos Filipe, Pedro
  • García-Illarramendi, Juan Manuel
  • Ramírez, Esther
  • Oliva Miguel, Baldomero
  • Farrés, Judith
  • Daura, Xavier
  • Mas, José Manuel
  • Morales-Barrera, Rafael
Oncology treatments require continuous individual adjustment based on the measurement of multiple clinical parameters. Prediction tools exploiting the patterns present in the clinical data could be used to assist decision making and ease the burden associated to the interpretation of all these parameters. The goal of this study was to predict the evolution of patients with pancreatic cancer at their next visit using information routinely recorded in health records, providing a decision-support system for clinicians. We selected hematological variables as the visit's clinical outcomes, under the assumption that they can be predictive of the evolution of the patient. Multivariate models based on regression trees were generated to predict next-visit values for each of the clinical outcomes selected, based on the longitudinal clinical data as well as on molecular data sets streaming from in silico simulations of individual patient status at each visit. The models predict, with a mean prediction score (balanced accuracy) of 0.79, the evolution trends of eosinophils, leukocytes, monocytes, and platelets. Time span between visits and neutropenia were among the most common factors contributing to the predicted evolution. The inclusion of molecular variables from the systems-biology in silico simulations provided a molecular background for the observed variations in the selected outcome variables, mostly in relation to the regulation of hematopoiesis. In spite of its limitations, this study serves as a proof of concept for the application of next-visit prediction tools in real-world settings, even when available data sets are small., V.J. is part of a project (COSMIC) that has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 765158. P.M.F. receives funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 860303. J.M.G.I. receives funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 859962.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Methods to develop an in silico clinical trial: computational head-to-head comparison of lisdexamfetamine and methylphenidate

  • Gutiérrez-Casares, José Ramón
  • Quintero, Javier
  • Jorba Argemí, Guillem
  • Junet, Valentin
  • Martínez, Vicente
  • Pozo-Rubio, Tamara
  • Oliva Miguel, Baldomero
  • Daura, Xavier
  • Mas, José Manuel
  • Montoto, Carmen
Regulatory agencies encourage computer modeling and simulation to reduce the time and cost of clinical trials. Although still not classified in formal guidelines, system biology-based models represent a powerful tool for generating hypotheses with great molecular detail. Herein, we have applied a mechanistic head-to-head in silico clinical trial (ISCT) between two treatments for attention-deficit/hyperactivity disorder, to wit lisdexamfetamine (LDX) and methylphenidate (MPH). The ISCT was generated through three phases comprising (i) the molecular characterization of drugs and pathologies, (ii) the generation of adult and children virtual populations (vPOPs) totaling 2,600 individuals and the creation of physiologically based pharmacokinetic (PBPK) and quantitative systems pharmacology (QSP) models, and (iii) data analysis with artificial intelligence methods. The characteristics of our vPOPs were in close agreement with real reference populations extracted from clinical trials, as did our PBPK models with in vivo parameters. The mechanisms of action of LDX and MPH were obtained from QSP models combining PBPK modeling of dosing schemes and systems biology-based modeling technology, i.e., therapeutic performance mapping system. The step-by-step process described here to undertake a head-to-head ISCT would allow obtaining mechanistic conclusions that could be extrapolated or used for predictions to a certain extent at the clinical level. Altogether, these computational techniques are proven an excellent tool for hypothesis-generation and would help reach a personalized medicine., This study was funded by Takeda. Public funders provided support for some of the authors' salaries: GJ has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 765912. VJ is part of a project (COSMIC; www.cosmic-h2020.eu) that has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 765158.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan

  • Jorba, Guillem|||0000-0001-5209-5353
  • Aguirre-Plans, Joaquim|||0000-0002-1971-1350
  • Junet, Valentin|||0000-0002-6138-0612
  • Segú-Vergés, Cristina|||0000-0002-8215-872X
  • Ruiz, José Luis
  • Pujol, Albert
  • Fernández-Fuentes, Narcís
  • Mas, José Manuel
  • Oliva Miguel, Baldomero|||0000-0003-0702-0250
Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism. However, in complex diseases such as heart diseases there is not a unique mechanism of action but a wide range of different responses depending on the patient. Exploring this collection of mechanisms is one of the clues for a future personalized medicine. The Therapeutic Performance Mapping System (TPMS) is a Systems Biology approach that generates multiple models of the mechanism of action of a drug. Each molecular mechanism generated could be associated to particular individuals, here defined as prototype-patients, hence the generation of models using TPMS technology may be used for detecting adverse effects to specific patients. TPMS operates by (1) modelling the responses in humans with an accurate description of a protein network and (2) applying a Multilayer Perceptron-like and sampling strategy to find all plausible solutions. In the present study, TPMS is applied to explore the diversity of mechanisms of action of the drug combination sacubitril/valsartan. We use TPMS to generate a wide range of models explaining the relationship between sacubitril/valsartan and heart failure (the indication), as well as evaluating their association with macular degeneration (a potential adverse effect). Among the models generated, we identify a set of mechanisms of action associated to a better response in terms of heart failure treatment, which could also be associated to macular degeneration development. Finally, a set of 30 potential biomarkers are proposed to identify mechanisms (or prototype-patients) more prone of suffering macular degeneration when presenting good heart failure response. All prototype-patients models generated are completely theoretical and therefore they do not necessarily involve clinical effects in real patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CuBlock, a cross-platform normalization method for gene-expression microarrays

  • Junet, Valentin|||0000-0002-6138-0612
  • Farrés, Judith|||0000-0002-0958-0510
  • Mas, José M.
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
Cross-(multi)platform normalization of gene-expression microarray data remains an unresolved issue. Despite the existence of several algorithms, they are either constrained by the need to normalize all samples of all platforms together, compromising scalability and reuse, by adherence to the platforms of a specific provider, or simply by poor performance. In addition, many of the methods presented in the literature have not been specifically tested against multi-platform data and/or other methods applicable in this context. Thus, we set out to develop a normalization algorithm appropriate for gene-expression studies based on multiple, potentially large microarray sets collected along multiple platforms and at different times, applicable in systematic studies aimed at extracting knowledge from the wealth of microarray data available in public repositories; for example, for the extraction of Real-World Data to complement data from Randomized Controlled Trials. Our main focus or criterion for performance was on the capacity of the algorithm to properly separate samples from different biological groups. We present CuBlock, an algorithm addressing this objective, together with a strategy to validate cross-platform normalization methods. To validate the algorithm and benchmark it against existing methods, we used two distinct datasets, one specifically generated for testing and standardization purposes and one from an actual experimental study. Using these datasets, we benchmarked CuBlock against ComBat (), UPC (), YuGene (), DBNorm (), Shambhala () and a simple log transform as reference. We note that many other popular normalization methods are not applicable in this context. CuBlock was the only algorithm in this group that could always and clearly differentiate the underlying biological groups after mixing the data, from up to six different platforms in this study. CuBlock can be downloaded from . are available at Bioinformatics online.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

IgIDivA, immunoglobulin intraclonal diversification analysis

  • Zaragoza-Infante, Laura|||0000-0003-0207-257X
  • Junet, Valentin|||0000-0002-6138-0612
  • Pechlivanis, Nikos
  • Fragkouli, Styliani-Christina|||0000-0003-4067-7123
  • Amprachamian, Serovpe
  • Koletsa, Triantafyllia
  • Chatzidimitriou, Anastasia
  • Papaioannou, Maria
  • Stamatopoulos, Kostas|||0000-0001-8529-640X
  • Agathangelidis, Andreas
  • Psomopoulos, Fotis|||0000-0002-0222-4273
Intraclonal diversification (ID) within the immunoglobulin (IG) genes expressed by B cell clones arises due to ongoing somatic hypermutation (SHM) in a context of continuous interactions with antigen(s). Defining the nature and order of appearance of SHMs in the IG genes can assist in improved understanding of the ID process, shedding light into the ontogeny and evolution of B cell clones in health and disease. Such endeavor is empowered thanks to the introduction of high-throughput sequencing in the study of IG gene repertoires. However, few existing tools allow the identification, quantification and characterization of SHMs related to ID, all of which have limitations in their analysis, highlighting the need for developing a purpose-built tool for the comprehensive analysis of the ID process. In this work, we present the immunoglobulin intraclonal diversification analysis (IgIDivA) tool, a novel methodology for the in-depth qualitative and quantitative analysis of the ID process from high-throughput sequencing data. IgIDivA identifies and characterizes SHMs that occur within the variable domain of the rearranged IG genes and studies in detail the connections between identified SHMs, establishing mutational pathways. Moreover, it combines established and new graph-based metrics for the objective determination of ID level, combined with statistical analysis for the comparison of ID level features for different groups of samples. Of importance, IgIDivA also provides detailed visualizations of ID through the generation of purpose-built graph networks. Beyond the method design, IgIDivA has been also implemented as an R Shiny web application. IgIDivA is freely available at https://bio.tools/igidiva
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A decision support system based on artificial intelligence and systems biology for the simulation of pancreatic cancer patient status

  • Junet, Valentin|||0000-0002-6138-0612
  • Matos-Filipe, Pedro|||0000-0003-0492-0683
  • García Illarramendi, Juan Manuel|||0000-0003-3368-814X
  • Ramírez, Esther
  • Oliva Miguel, Baldomero|||0000-0003-0702-0250
  • Farrés, Judith
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Mas, José Manuel
  • Morales, Rafael
Oncology treatments require continuous individual adjustment based on the measurement of multiple clinical parameters. Prediction tools exploiting the patterns present in the clinical data could be used to assist decision making and ease the burden associated to the interpretation of all these parameters. The goal of this study was to predict the evolution of patients with pancreatic cancer at their next visit using information routinely recorded in health records, providing a decision-support system for clinicians. We selected hematological variables as the visit's clinical outcomes, under the assumption that they can be predictive of the evolution of the patient. Multivariate models based on regression trees were generated to predict next-visit values for each of the clinical outcomes selected, based on the longitudinal clinical data as well as on molecular data sets streaming from in silico simulations of individual patient status at each visit. The models predict, with a mean prediction score (balanced accuracy) of 0.79, the evolution trends of eosinophils, leukocytes, monocytes, and platelets. Time span between visits and neutropenia were among the most common factors contributing to the predicted evolution. The inclusion of molecular variables from the systems-biology in silico simulations provided a molecular background for the observed variations in the selected outcome variables, mostly in relation to the regulation of hematopoiesis. In spite of its limitations, this study serves as a proof of concept for the application of next-visit prediction tools in real-world settings, even when available data sets are small.